

Markus S Anker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10128066/publications.pdf>

Version: 2024-02-01

63
papers

2,929
citations

279701

23
h-index

182361

51
g-index

63
all docs

63
docs citations

63
times ranked

4042
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	2.9	490
2	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Association of Gerontology and Geriatrics on behalf of the Heart Failure Association of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 1504-1524.	2.9	364
3	Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 507-509.	2.9	234
4	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	210
5	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	2.9	184
6	Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. <i>Nature Biotechnology</i> , 2021, 39, 705-716.	9.4	138
7	Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 22-34.	2.9	129
8	Weight loss, malnutrition, and cachexia in COVID-19: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 9-13.	2.9	113
9	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1242-1249.	2.9	90
10	Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. <i>European Journal of Heart Failure</i> , 2016, 18, 1524-1534.	2.9	76
11	Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. <i>International Journal of Cardiology</i> , 2017, 238, 5-11.	0.8	70
12	Muscle Wasting and Sarcopenia in Heart Failure – The Current State of Science. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6549.	1.8	68
13	Heart failure in the last year: progress and perspective. <i>ESC Heart Failure</i> , 2020, 7, 3505-3530.	1.4	62
14	TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 1447-1452.	0.8	52
15	Metabolic disorders in heart failure and cancer. <i>ESC Heart Failure</i> , 2018, 5, 1092-1098.	1.4	47
16	Cancer and heart failure – more than meets the eye: common risk factors and comorbidities. <i>European Journal of Heart Failure</i> , 2018, 20, 1382-1384.	2.9	34
17	Recent advances in cardio-oncology: a report from the Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019™. <i>ESC Heart Failure</i> , 2019, 6, 1140-1148.	1.4	34

#	ARTICLE	IF	CITATIONS
19	Biomarkers for Chronic Heart Failure. Herz, 2009, 34, 589-593.	0.4	33
20	Anemia in chronic heart failure: Can we treat? What to treat?. Heart Failure Reviews, 2012, 17, 203-210.	1.7	33
21	A year in heart failure: an update of recent findings. ESC Heart Failure, 2021, 8, 4370-4393.	1.4	28
22	Systolicâ€“diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 235, 11-16.	0.8	26
23	State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Archives of Medical Science, 2013, 1, 166-171.	0.4	25
24	The difference in referencing in <scp>Web of Science</scp>, <scp>Scopus</scp>, and <scp>Google Scholar</scp>. ESC Heart Failure, 2019, 6, 1291-1312.	1.4	25
25	Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. International Journal of Cardiology, 2013, 162, 73-76.	0.8	23
26	Modernâ€“day cardioâ€“oncology: a report from the â€“Heart Failure and World Congress on Acute Heart Failure 2018â€™. ESC Heart Failure, 2018, 5, 1083-1091.	1.4	23
27	Increased resting heart rate and prognosis in treatmentâ€“naïve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	2.9	23
28	Heart failure with preserved ejection fraction according to the HFAâ€“PEFF score in COVID â€“19 patients: clinical correlates and echocardiographic findings. European Journal of Heart Failure, 2021, 23, 1891-1902.	2.9	21
29	Advanced cancer is also a heart failure syndrome: a hypothesis. European Journal of Heart Failure, 2021, 23, 140-144.	2.9	20
30	Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 238, 140-143.	0.8	19
31	Cardiac cachexia. European Heart Journal Supplements, 2019, 21, L24-L27.	0.0	19
32	Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. European Journal of Heart Failure, 2021, 23, 145-153.	2.9	18
33	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. International Journal of Cardiology, 2017, 227, 462-466.	0.8	16
34	Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma. ESC Heart Failure, 2019, 6, 824-829.	1.4	14
35	Assessment of coronary artery disease during hospitalization for cancer treatment. Clinical Research in Cardiology, 2021, 110, 200-210.	1.5	14
36	Advanced cancer is also a heart failure syndrome: a hypothesis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 533-537.	2.9	13

#	ARTICLE	IF	CITATIONS
37	Cardiac cachexia: the mandate to increase clinician awareness. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 298-304.	0.5	11
38	What do patients with heart failure die from? A single assassin or a conspiracy?. <i>European Journal of Heart Failure</i> , 2020, 22, 26-28.	2.9	11
39	Updates in heart failure: what last year brought to us. <i>ESC Heart Failure</i> , 2018, 5, 989-1007.	1.4	10
40	Roxadustat for Anemia in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, e3.	13.9	10
41	Management of Chronic Cardiorenal Syndrome. <i>Contributions To Nephrology</i> , 2010, 165, 129-139.	1.1	7
42	Blocking myostatin: muscle mass equals muscle strength?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1396-1398.	2.9	7
43	Advances in cachexia and sarcopenia research in the heart failure context. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 860-862.	0.6	6
44	Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 793-801.	2.9	5
45	Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care. <i>Cancers</i> , 2021, 13, 2303.	1.7	5
46	ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity. <i>Cancers</i> , 2021, 13, 1197.	1.7	4
47	Smoking and Other Risk Factors in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018, 379, 2572-2575.	13.9	3
48	The Journal of Cachexia, Sarcopenia and Muscle stays the front-runner in geriatrics and gerontology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1151.	2.9	3
49	Liraglutide for Adolescents with Obesity. <i>New England Journal of Medicine</i> , 2020, 383, 1192-1194.	13.9	3
50	Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail. <i>European Heart Journal</i> , 2021, 42, 1637-1637.	1.0	3
51	Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment. <i>Polish Archives of Internal Medicine</i> , 2021, , .	0.3	3
52	JCSM: growing together with cachexia and sarcopenia research. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1359-1367.	2.9	3
53	Clinical problems of patients with cachexia due to chronic illness: a congress report. <i>ESC Heart Failure</i> , 2020, 7, 3414-3420.	1.4	2
54	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. <i>ESC Heart Failure</i> , 2020, 7, 873-877.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Novel biomarkers in heart failure and cardio-oncology. <i>Kardiologia Polska</i> , 2019, 77, 329-330.	0.3	2
56	The 10th year of the <i>Journal of Cachexia, Sarcopenia and Muscle</i> . <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1390-1395.	2.9	2
57	Long-term prognostic value of vasodilator stress cardiac magnetic resonance in patients with atrial fibrillation. <i>ESC Heart Failure</i> , 2022, 9, 110-121.	1.4	2
58	Treatment of systolic hypertension and low diastolic blood pressure in older adults: How low is too low?!. <i>International Journal of Cardiology</i> , 2017, 242, 21.	0.8	1
59	ESC Heart Failure receives its first impact factor. <i>European Journal of Heart Failure</i> , 2019, 21, 1490.	2.9	1
60	ESC Heart Failure increases its impact factor. <i>ESC Heart Failure</i> , 2020, 7, 3421-3426.	1.4	1
61	The new Heart Failure Association journal – ESC Heart Failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1657-1663.	2.9	0
62	Reply to “Heart failure with preserved ejection fraction and COVID-19: which comes first, the chicken or the egg?”. <i>European Journal of Heart Failure</i> , 2021, 23, 2092-2093.	2.9	0
63	The importance of registries in today's heart failure therapies. <i>Kardiologia Polska</i> , 2018, 76, 1029-1030.	0.3	0